Aurora Cannabis, as a major player in the cannabis industry, is directly impacted by regulatory changes and perceptions around marijuana's medical value. The DEA's mixed message could lead to market uncertainty, affecting investor sentiment and potentially the stock's short-term performance.

Canopy Growth Corporation's stock could be affected by the DEA's recent statements, as regulatory attitudes towards marijuana's medical use directly influence the cannabis market. The DEA's skepticism, even with the rescheduling recommendation, introduces a level of uncertainty that could impact investor confidence and stock performance in the short term.

Tilray Brands, Inc., as a significant cannabis company, is sensitive to regulatory changes and public statements about marijuana's medical efficacy. The DEA's contradictory stance could lead to investor hesitancy, affecting Tilray's stock price in the short term due to the regulatory uncertainty.